Abstract Library

#2944 Soluble ST2 (sST2) Levels in the Management of Carcinoid Heart Disease in Patients with Neuroendocrine Cancer

Introduction: The identification of a sensitive biomarker to detect the presence and severity of carcinoid heart disease could allow more selective use of clinical and echocardiographic screening. ST2 is a protein belonging to the family of interleukin 1 receptors, present both in the isoform of transmembrane (ST2L) and in the soluble one (sST2). sST2 blocks the anti-inflammatory, anti-hypertrophic, and anti-fibrotic effects of cytokine IL-33 on the myocardium and recent studies have shown that sST2 levels increase in the blood of patients diagnosed with heart failure.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Salvatici M, Zorzino L, Fabiani I, Cardinale D, Fazio N,

Keywords: sST2, Biomarkers, Carcinoid Heart Disease,

#2818 Is It That Rare?

Introduction: Carcinoid heart disease (CHD) is a rare and unique manifestation, It present in 50% of CS

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Babli S

Authors: Babli S, Alzahrani W, Aldawish M,

Keywords: neuroendocrine tumors, carcinoid syndrome, carcinoid heart disease,

#2260 Carcinoid Heart Failure in a Metastatic Duodenal Neuroendocrine Tumor: A Challenging Case Report.

Introduction: Carcinoid heart disease (CHD) is a potenzial fatal cardiac manifestation, characterized by fibrous endocardial thickening involving right-sided heart valves. In 70% of cases, CHD occurs in advanced small bowel NETs with carcinoid syndrome (CS). Serotonin seems to play a main role. Early recognition and surgical intervention may improve the outcome of patients.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Brizzi M

Authors: Brizzi M, La Salvia A, Parisi F, Scagliotti G,

Keywords: Carcinoid Hearth Disease, Carcinoid syndrome, Surgery, somatostatin analogues,

#1818 Patient Outcomes after Cardiac Surgery for Carcinoid Heart Disease Are Dependant Upon Successful Cytoreductive Multimodal Treatment and Control of Metastatic Neuroendocrine Disease

Introduction: Carcinoid Heart Disease (CHD) as a result of long standing carcinoid syndrome is associated with a poor prognosis due to development of valvular incompetence & right heart failure. Cardiac valve surgery is the main therapeutic option.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Jaber B, Ramsey E, Cowburn P, Tsang G, Armstrong T,

Keywords: Carcinoid heart disease, surgery,

#1586 Biomarkers for Carcinoid Heart Disease

Introduction: Carcinoid heart disease (CHD) develops in patients with carcinoid syndrome. Currently NT-proBNP (NTP) is suggested as the best current biomarker to screen for CHD and monitor heart failure. A number of other markers have been investigated for heart failure.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Srirajaskanthan R

Authors: Basuroy R, Srirajaskanthan R, Ramage J, Sherwood R,

Keywords: carcinoid heart disease,